ACT225 Biotherapeutics (ACT225 BioTx) is a biotechnology company focused on the development of targeted theranostic (“therapy and diagnostic”) radiopharmaceuticals for precision oncology. Our lead programs address an unmet need for effective therapies in solid tumors such as colorectal cancer, pancreatic cancer, triple-negative breast cancer and non-small cell lung cancer.

ACT225 BioTx is advancing best-in-class radiopharmaceuticals that overcome cancer resistance mechanisms leading to enhanced effectiveness and excellent safety profiles in preclinical studies. ACT225 BioTx is concurrently developing diagnostic radiopharmaceuticals to allow for more accurate patient selection, target quantification, personalization of therapeutic dose, and monitoring of treatment responses.